The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial

{ 'institution': [{'name': 'Research Square'}], 'indexed': { 'date-parts': [[2021, 12, 22]], 'date-time': '2021-12-22T11:08:24Z', 'timestamp': 1640171304292}, 'posted': {'date-parts': [[2021, 4, 27]]}, 'group-title': 'In Review', 'reference-count': 0, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2021, 4, 27]], 'date-time': '2021-04-27T00:00:00Z', 'timestamp': 1619481600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'accepted': {'date-parts': [[2021, 4, 25]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>IntroductionAs the first randomized clinical trial, this study evaluated the ' 'effect of Famotidine on the improvement of outcomes of hospitalized patients with ' 'COVID-19.MethodThis phase III randomized clinical trial was designed with two parallel arms, ' 'placebo-controlled, single-blind, and concealed allocation, and recruited 20 patients. Oral ' 'Famotidine 160 mg four times a day was given to patients until the discharge day or for a ' 'maximum of 14 days. Patients’ temperature, respiration rate, oxygen saturation, lung ' 'infiltration, lactate dehydrogenase (LDH) level and complete blood count (CBC) were measured ' 'at the baseline (before the intervention) and on day 14 after the intervention or on ' 'discharge day. Length of stay in the hospital and length of stay in the ICU were also ' 'measured as secondary outcomes of the study.ResultsThe results showed a significant decrease ' 'in LDH (P\u2009=\u20090.01), mean WBC (P\u2009=\u20090.04) and length of stay (P\u2009=\u2009' '0.04) of patients with COVID-19 in the group treated with Famotidine compared to the control ' 'group. There was also a significant increase in oxygen saturation (P\u2009=\u20090.01) in the ' 'group treated with Famotidine compared to the control group. Cough improvement was also ' 'higher in the oral Famotidine group compared to the control group (P\u2009=\u2009' '0.02).ConclusionThis was the first clinical trial on the effect of Famotidine on the ' 'improvement of hospitalized COVID-19 patients, which indicated that high-dose Famotidine ' 'improves patients’ clinical signs and reduces the severity of the disease and duration of ' 'hospitalization.</jats:p>', 'DOI': '10.21203/rs.3.rs-462937/v1', 'type': 'posted-content', 'created': {'date-parts': [[2021, 4, 27]], 'date-time': '2021-04-27T18:12:40Z', 'timestamp': 1619547160000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': [ 'The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A\xa0' 'phase III randomised clinical trial'], 'prefix': '10.21203', 'author': [ { 'given': 'Hamid Reza', 'family': 'Samimagham', 'sequence': 'first', 'affiliation': [{'name': 'Hormozgan University of Medical Sciences'}]}, { 'given': 'Mehdi Hassani', 'family': 'Azad', 'sequence': 'additional', 'affiliation': [{'name': 'Hormozgan University of Medical Sciences'}]}, { 'given': 'Maryam', 'family': 'Haddad', 'sequence': 'additional', 'affiliation': [{'name': 'Hormozgan University of Medical Sciences'}]}, { 'given': 'Mohsen', 'family': 'Arabi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Iran University of Medical Sciences: Tehran University of ' 'Medical Sciences'}]}, { 'given': 'Dariush', 'family': 'Hooshyar', 'sequence': 'additional', 'affiliation': [{'name': 'Hormozgan University of Medical Sciences Faculty of Medicine'}]}, { 'given': 'Mitra', 'family': 'KazemiJahromi', 'sequence': 'additional', 'affiliation': [{'name': 'Hormozgan University of Medical Sciences'}]}], 'member': '8761', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-462937/v1', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-462937/v1.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 11, 16]], 'date-time': '2021-11-16T05:33:32Z', 'timestamp': 1637040812000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 4, 27]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-462937/v1', 'relation': {}, 'published': {'date-parts': [[2021, 4, 27]]}, 'subtype': 'preprint'}